Institute of Endocrinology, Beilinson Hospital, Rabin Medical Center, Petah Tikva 49100, Israel.
J Endocrinol Invest. 2010 Nov;33(10):739-44. doi: 10.1007/BF03346680. Epub 2010 May 17.
Chromaffin-cell tumors (CCT), a rare group of catecholamine producing endocrine neoplasms, are traditionally suspected and diagnosed in patients presenting with episodic hypertension, together with the classic triad of headache, sweating, and tachycardia. Asymptomatic CCT are increasingly diagnosed, frequently as "incidentalomas". We have conducted a multicenter retrospective study, to assess the characteristics of a group of patients with clinically silent CCT, compared with a group of patients with typical CCT.
Forty-three consecutive patients with CCT (24 with silent and 19 with typical tumors) have been retrospectively studied for a period of up to 20 yr (between 1989 and 2009); clinical picture, biochemical tests, as well as topographic and functional assessment were analyzed at diagnosis and periodically following treatment. Surgical samples were reviewed for neuroendocrine markers and for signs of invasiveness.
Patients with clinically silent CCT were significantly older than the typical ones (56.3±3.4 vs 48.0±4.8 yr; p<0.05); 15 of them (63%) were completely asymptomatic, and 9 patients (37%) complained of non-specific abdominal symptoms. Hypertension was present in only 6 silent CCT patients (25%), it was well controlled [mean blood pressure (BP) 134/84 mmHg], and persisted after surgery in only 2 patients. Fourteen out of twenty-four silent CCT patients (58%) were managed pre-operatively with prophylactic combination of α and β blockade, despite normal BP values. Clinically silent CCT were larger than typical CCT (mean diameter of 5.2±2.3 cm vs 4.6±1.5 cm, p<0.05) and secreted higher a mounts of normeta neph rines. All clinically silent CCT patients were defined as "cured" after surgery.
Clinically silent CCT are more prevalent than previously reported. With an adequate pre-surgical diagnosis and patient preparation, the prognosis of silent tumors is usually excellent.
嗜铬细胞瘤(CCT)是一种罕见的儿茶酚胺产生的内分泌肿瘤,传统上怀疑并诊断为在发作性高血压的患者中,伴有头痛、出汗和心动过速的经典三联征。无症状的 CCT 越来越多地被诊断出来,通常作为“偶发瘤”。我们进行了一项多中心回顾性研究,以评估一组临床表现为无症状 CCT 的患者的特征,与一组具有典型 CCT 的患者进行比较。
回顾性研究了 43 例连续 CCT 患者(24 例为无症状肿瘤,19 例为典型肿瘤),时间长达 20 年(1989 年至 2009 年);在诊断时以及治疗后定期分析临床症状、生化检查、以及影像学和功能评估。手术标本进行神经内分泌标志物和侵袭性的检查。
临床表现为无症状 CCT 的患者明显比有症状的患者年龄大(56.3±3.4 岁 vs 48.0±4.8 岁;p<0.05);其中 15 例(63%)完全无症状,9 例(37%)有非特异性腹部症状。仅 6 例(25%)无症状 CCT 患者存在高血压,血压控制良好[平均血压(BP)134/84mmHg],术后仅 2 例患者持续存在高血压。24 例无症状 CCT 患者中有 14 例(58%)尽管血压正常,术前仍预防性联合使用α和β阻滞剂治疗。临床表现为无症状 CCT 的肿瘤比有症状 CCT 的肿瘤更大(平均直径为 5.2±2.3cm 比 4.6±1.5cm,p<0.05),并分泌更高量的去甲肾上腺素。所有临床表现为无症状的 CCT 患者术后均被定义为“治愈”。
临床表现为无症状的 CCT 比以前报道的更为常见。通过适当的术前诊断和患者准备,无症状肿瘤的预后通常良好。